ID   SAHH2_HUMAN             Reviewed;         530 AA.
AC   O43865; B4E168; Q2TAJ6; Q502W8; Q5VSM0; Q6P171; Q96PK4; Q9UG84;
DT   15-DEC-1998, integrated into UniProtKB/Swiss-Prot.
DT   04-APR-2006, sequence version 2.
DT   07-APR-2021, entry version 197.
DE   RecName: Full=S-adenosylhomocysteine hydrolase-like protein 1 {ECO:0000312|HGNC:HGNC:344};
DE   AltName: Full=DC-expressed AHCY-like molecule;
DE   AltName: Full=IP(3)Rs binding protein released with IP(3);
DE            Short=IRBIT;
DE   AltName: Full=Putative adenosylhomocysteinase 2;
DE   AltName: Full=S-adenosyl-L-homocysteine hydrolase 2;
DE            Short=AdoHcyase 2;
GN   Name=AHCYL1 {ECO:0000312|HGNC:HGNC:344};
GN   Synonyms=DCAL, IRBIT, XPVKONA {ECO:0000312|HGNC:HGNC:344};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), TISSUE SPECIFICITY, AND
RP   DEVELOPMENTAL STAGE.
RX   PubMed=11904675; DOI=10.1007/s00251-001-0402-z;
RA   Dekker J.W., Budhia S., Angel N.Z., Cooper B.J., Clark G.J., Hart D.N.,
RA   Kato M.;
RT   "Identification of an S-adenosylhomocysteine hydrolase-like transcript
RT   induced during dendritic cell differentiation.";
RL   Immunogenetics 53:993-1001(2002).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Kidney, and Thalamus;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Brain;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D.,
RA   Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A.,
RA   Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D., Dunham A.,
RA   Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A., Jones M.C., Gillson C.,
RA   Searle S., Zhou Y., Kokocinski F., McDonald L., Evans R., Phillips K.,
RA   Atkinson A., Cooper R., Jones C., Hall R.E., Andrews T.D., Lloyd C.,
RA   Ainscough R., Almeida J.P., Ambrose K.D., Anderson F., Andrew R.W.,
RA   Ashwell R.I.S., Aubin K., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Beasley H., Bethel G., Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J.,
RA   Buckley D., Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y.,
RA   Clarke G., Clee C., Cobley V., Collier R.E., Corby N., Coville G.J.,
RA   Davies J., Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R., Hammond S.,
RA   Harrison E.S.I., Hart E., Haugen E., Heath P.D., Holmes S., Holt K.,
RA   Howden P.J., Hunt A.R., Hunt S.E., Hunter G., Isherwood J., James R.,
RA   Johnson C., Johnson D., Joy A., Kay M., Kershaw J.K., Kibukawa M.,
RA   Kimberley A.M., King A., Knights A.J., Lad H., Laird G., Lawlor S.,
RA   Leongamornlert D.A., Lloyd D.M., Loveland J., Lovell J., Lush M.J.,
RA   Lyne R., Martin S., Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W.,
RA   McLaren S., Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C., Subramanian S.,
RA   Sycamore N., Tracey A., Tromans A., Van Helmond Z., Wall M., Wallis J.M.,
RA   White S., Whitehead S.L., Wilkinson J.E., Willey D.L., Williams H.,
RA   Wilming L., Wray P.W., Wu Z., Coulson A., Vaudin M., Sulston J.E.,
RA   Durbin R.M., Hubbard T., Wooster R., Dunham I., Carter N.P., McVean G.,
RA   Ross M.T., Harrow J., Olson M.V., Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND NUCLEOTIDE SEQUENCE
RP   [LARGE SCALE MRNA] OF 48-251 (ISOFORM 2).
RC   TISSUE=Brain, Colon, Eye, Placenta, PNS, and Testis;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 16-530 (ISOFORM 1).
RC   TISSUE=Skin;
RA   Volpe J.P.G., McDowell M., Jostes R.F., Afzal V., Sadinski W., Trask B.J.,
RA   Legerski R., Cleaver J.E.;
RT   "Complementation of chromosomal instability in the xeroderma pigmentosum
RT   variant by a gene on human chromosome 1 with homology to S-adenosyl
RT   homocysteine hydrolase.";
RL   Submitted (DEC-1996) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 48-164 (ISOFORM 2).
RC   TISSUE=Chondrocyte;
RX   PubMed=12878157; DOI=10.1016/s0014-4827(03)00130-7;
RA   Imabayashi H., Mori T., Gojo S., Kiyono T., Sugiyama T., Irie R.,
RA   Isogai T., Hata J., Toyama Y., Umezawa A.;
RT   "Redifferentiation of dedifferentiated chondrocytes and chondrogenesis of
RT   human bone marrow stromal cells via chondrosphere formation with expression
RT   profiling by large-scale cDNA analysis.";
RL   Exp. Cell Res. 288:35-50(2003).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 48-105 (ISOFORM 2).
RC   TISSUE=Testis;
RX   PubMed=7782076; DOI=10.1016/0888-7543(95)80096-5;
RA   Pawlak A., Toussaint C., Levy I., Bulle F., Poyard M., Barouki R.,
RA   Guellaen G.;
RT   "Characterization of a large population of mRNAs from human testis.";
RL   Genomics 26:151-158(1995).
RN   [10]
RP   IDENTIFICATION (ISOFORM 2).
RX   PubMed=16754674; DOI=10.1074/jbc.m602520200;
RA   Cooper B.J., Key B., Carter A., Angel N.Z., Hart D.N.J., Kato M.;
RT   "Suppression and overexpression of adenosylhomocysteine hydrolase-like
RT   protein 1 (AHCYL1) influences zebrafish embryo development: a possible role
RT   for AHCYL1 in inositol phospholipid signaling.";
RL   J. Biol. Chem. 281:22471-22484(2006).
RN   [11]
RP   FUNCTION, SUBUNIT, INTERACTION WITH ITPR1, PHOSPHORYLATION AT SER-68 AND
RP   SER-71, AND MUTAGENESIS OF SER-64; SER-66; SER-68; SER-70; SER-71; THR-72;
RP   SER-74; SER-76; SER-77; SER-80; THR-82; SER-84; SER-85; SER-90 AND THR-97.
RX   PubMed=16793548; DOI=10.1016/j.molcel.2006.05.017;
RA   Ando H., Mizutani A., Kiefer H., Tsuzurugi D., Michikawa T., Mikoshiba K.;
RT   "IRBIT suppresses IP3 receptor activity by competing with IP3 for the
RT   common binding site on the IP3 receptor.";
RL   Mol. Cell 22:795-806(2006).
RN   [12]
RP   FUNCTION, INTERACTION WITH SLC4A4, AND MUTAGENESIS OF THR-52; THR-58;
RP   SER-62; SER-64; SER-66; SER-68; SER-70; SER-71; THR-72; SER-74; SER-76;
RP   SER-77; SER-80; THR-82; SER-84; SER-85; SER-90 AND THR-97.
RX   PubMed=16769890; DOI=10.1073/pnas.0602250103;
RA   Shirakabe K., Priori G., Yamada H., Ando H., Horita S., Fujita T.,
RA   Fujimoto I., Mizutani A., Seki G., Mikoshiba K.;
RT   "IRBIT, an inositol 1,4,5-trisphosphate receptor-binding protein,
RT   specifically binds to and activates pancreas-type Na+/HCO3-cotransporter 1
RT   (pNBC1).";
RL   Proc. Natl. Acad. Sci. U.S.A. 103:9542-9547(2006).
RN   [13]
RP   FUNCTION, AND INTERACTION WITH SLC9A3.
RX   PubMed=18829453; DOI=10.1074/jbc.m805534200;
RA   He P., Zhang H., Yun C.C.;
RT   "IRBIT, inositol 1,4,5-triphosphate (IP3) receptor-binding protein released
RT   with IP3, binds Na+/H+ exchanger NHE3 and activates NHE3 activity in
RT   response to calcium.";
RL   J. Biol. Chem. 283:33544-33553(2008).
RN   [14]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-391, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [15]
RP   FUNCTION, INTERACTION WITH FIP1L1 AND PAPOLA, RNA-BINDING, AND MUTAGENESIS
RP   OF SER-62; SER-64; SER-66; SER-68; SER-70; SER-71; THR-72; SER-74; SER-76;
RP   SER-77; SER-80; THR-82; SER-84; SER-85; SER-90 AND THR-97.
RX   PubMed=19224921; DOI=10.1074/jbc.m807136200;
RA   Kiefer H., Mizutani A., Iemura S., Natsume T., Ando H., Kuroda Y.,
RA   Mikoshiba K.;
RT   "Inositol 1,4,5-triphosphate receptor-binding protein released with
RT   inositol 1,4,5-triphosphate (IRBIT) associates with components of the mRNA
RT   3' processing machinery in a phosphorylation-dependent manner and inhibits
RT   polyadenylation.";
RL   J. Biol. Chem. 284:10694-10705(2009).
RN   [16]
RP   INTERACTION WITH AHCYL2 AND ITPR1, AND PHOSPHORYLATION AT SER-68; SER-71;
RP   SER-74 AND SER-77.
RX   PubMed=19220705; DOI=10.1111/j.1471-4159.2009.05979.x;
RA   Ando H., Mizutani A., Mikoshiba K.;
RT   "An IRBIT homologue lacks binding activity to inositol 1,4,5-trisphosphate
RT   receptor due to the unique N-terminal appendage.";
RL   J. Neurochem. 109:539-550(2009).
RN   [17]
RP   FUNCTION, INTERACTION WITH SLC9A3, AND MUTAGENESIS OF SER-68; SER-71 AND
RP   SER-74.
RX   PubMed=20584908; DOI=10.1074/jbc.m110.133066;
RA   He P., Klein J., Yun C.C.;
RT   "Activation of Na+/H+ exchanger NHE3 by angiotensin II is mediated by
RT   inositol 1,4,5-triphosphate (IP3) receptor-binding protein released with
RT   IP3 (IRBIT) and Ca2+/calmodulin-dependent protein kinase II.";
RL   J. Biol. Chem. 285:27869-27878(2010).
RN   [18]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [19]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT SER-2, PHOSPHORYLATION [LARGE SCALE
RP   ANALYSIS] AT SER-2, CLEAVAGE OF INITIATOR METHIONINE [LARGE SCALE
RP   ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T.,
RA   Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.;
RT   "System-wide temporal characterization of the proteome and phosphoproteome
RT   of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [20]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1 (ISOFORM 2), AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22814378; DOI=10.1073/pnas.1210303109;
RA   Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A.,
RA   Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E., Timmerman E.,
RA   Prieto J., Arnesen T., Sherman F., Gevaert K., Aldabe R.;
RT   "N-terminal acetylome analyses and functional insights of the N-terminal
RT   acetyltransferase NatB.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012).
RN   [21]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-2, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [22]
RP   FUNCTION, INTERACTION WITH BCL2L10 AND ITPR1, SUBCELLULAR LOCATION,
RP   PHOSPHORYLATION AT SER-68; SER-71; SER-74 AND SER-77, DEPHOSPHORYLATION,
RP   AND MUTAGENESIS OF SER-68.
RX   PubMed=27995898; DOI=10.7554/elife.19896;
RA   Bonneau B., Ando H., Kawaai K., Hirose M., Takahashi-Iwanaga H.,
RA   Mikoshiba K.;
RT   "IRBIT controls apoptosis by interacting with the Bcl-2 homolog, Bcl2l10,
RT   and by promoting ER-mitochondria contact.";
RL   Elife 5:e19896-e19896(2016).
RN   [23]
RP   INTERACTION WITH ZCCHC4.
RX   PubMed=31799605; DOI=10.1093/nar/gkz1147;
RA   Pinto R., Vaagboe C.B., Jakobsson M.E., Kim Y., Baltissen M.P.,
RA   O'Donohue M.F., Guzman U.H., Malecki J.M., Wu J., Kirpekar F., Olsen J.V.,
RA   Gleizes P.E., Vermeulen M., Leidel S.A., Slupphaug G., Falnes P.O.;
RT   "The human methyltransferase ZCCHC4 catalyses N6-methyladenosine
RT   modification of 28S ribosomal RNA.";
RL   Nucleic Acids Res. 48:830-846(2020).
RN   [24]
RP   X-RAY CRYSTALLOGRAPHY (2.64 ANGSTROMS) OF 89-530 OF MUTANT ALA-508 IN
RP   COMPLEX WITH NAD, COFACTOR, FUNCTION, INTERACTION WITH RRM1, MISCELLANEOUS,
RP   PEST REGION, AND PHOSPHORYLATION.
RX   PubMed=25237103; DOI=10.1126/science.1251550;
RA   Arnaoutov A., Dasso M.;
RT   "Enzyme regulation. IRBIT is a novel regulator of ribonucleotide reductase
RT   in higher eukaryotes.";
RL   Science 345:1512-1515(2014).
CC   -!- FUNCTION: Multifaceted cellular regulator which coordinates several
CC       essential cellular functions including regulation of epithelial HCO3(-)
CC       and fluid secretion, mRNA processing and DNA replication. Regulates
CC       ITPR1 sensitivity to inositol 1,4,5-trisphosphate, competing for the
CC       common binding site and acting as endogenous 'pseudoligand' whose
CC       inhibitory activity can be modulated by its phosphorylation status.
CC       Promotes the formation of contact points between the endoplasmic
CC       reticulum (ER) and mitochondria, facilitating transfer of Ca(2+) from
CC       the ER to mitochondria (PubMed:27995898). Under normal cellular
CC       conditions, functions cooperatively with BCL2L10 to limit ITPR1-
CC       mediated Ca(2+) release but, under apoptotic stress conditions,
CC       dephosphorylated which promotes dissociation of both AHCYL1 and BCL2L10
CC       from mitochondria-associated endoplasmic reticulum membranes, inhibits
CC       BCL2L10 interaction with ITPR1 and leads to increased Ca(2+) transfer
CC       to mitochondria which promotes apoptosis (PubMed:27995898). In the
CC       pancreatic and salivary ducts, at resting state, attenuates inositol
CC       1,4,5-trisphosphate-induced calcium release by interacting with ITPR1
CC       (PubMed:16793548). When extracellular stimuli induce ITPR1
CC       phosphorylation or inositol 1,4,5-trisphosphate production, dissociates
CC       from ITPR1 to interact with CFTR and SLC26A6, mediating their
CC       synergistic activation by calcium and cAMP that stimulates the
CC       epithelial secretion of electrolytes and fluid (By similarity). Also
CC       activates basolateral SLC4A4 isoform 1 to coordinate fluid and HCO3(-)
CC       secretion (PubMed:16769890). Inhibits the effect of STK39 on SLC4A4 and
CC       CFTR by recruiting PP1 phosphatase which activates SLC4A4, SLC26A6 and
CC       CFTR through dephosphorylation (By similarity). Mediates the induction
CC       of SLC9A3 surface expression produced by Angiotensin-2
CC       (PubMed:20584908). Depending on the cell type, activates SLC9A3 in
CC       response to calcium or reverses SLC9A3R2-dependent calcium inhibition
CC       (PubMed:18829453). May modulate the polyadenylation state of specific
CC       mRNAs, both by controlling the subcellular location of FIP1L1 and by
CC       inhibiting PAPOLA activity, in response to a stimulus that alters its
CC       phosphorylation state (PubMed:19224921). Acts as a (dATP)-dependent
CC       inhibitor of ribonucleotide reductase large subunit RRM1, controlling
CC       the endogenous dNTP pool and ensuring normal cell cycle progression
CC       (PubMed:25237103). In vitro does not exhibit any S-adenosyl-L-
CC       homocysteine hydrolase activity (By similarity).
CC       {ECO:0000250|UniProtKB:B5DFN2, ECO:0000250|UniProtKB:Q80SW1,
CC       ECO:0000269|PubMed:16769890, ECO:0000269|PubMed:16793548,
CC       ECO:0000269|PubMed:18829453, ECO:0000269|PubMed:19224921,
CC       ECO:0000269|PubMed:20584908, ECO:0000269|PubMed:25237103,
CC       ECO:0000269|PubMed:27995898}.
CC   -!- COFACTOR:
CC       Name=NAD(+); Xref=ChEBI:CHEBI:57540;
CC         Evidence={ECO:0000269|PubMed:25237103};
CC       Note=Binds 1 NAD(+) per subunit. {ECO:0000269|PubMed:25237103};
CC   -!- SUBUNIT: Forms multimers (PubMed:16793548). Forms heteromultimers with
CC       AHCYL2 (via the C-terminal region) (PubMed:19220705). Interacts (when
CC       phosphorylated) with ITPR1 (when not phosphorylated); the interaction
CC       suppresses inositol 1,4,5-trisphosphate binding to ITPR1
CC       (PubMed:16793548, PubMed:27995898). Interacts with BCL2L10; this
CC       strengthens the interaction of AHCYL1 with ITPR1 (PubMed:27995898).
CC       Interacts with CFTR and SLC26A6; the interactions take place once
CC       AHCYL1 is released from ITPR1 and increase CFTR and SLC26A6 activities
CC       (By similarity). Interacts with RRM1; in a phosphorylation- and (dATP)-
CC       dependent manner. Interacts (via PEST domain when phosphorylated) with
CC       SLC4A4 isoform 1 but not isoform 2; the interaction increases SLC4A4
CC       isoform 1 activity (PubMed:16769890). Interacts (when phosphorylated)
CC       with SLC9A3; the interaction is required for SLC9A3 apical location and
CC       activity (PubMed:18829453, PubMed:20584908). Interacts (when
CC       phosphorylated) with FIP1L1; the interaction is direct and associates
CC       AHCYL1 with the CPSF complex and RNA (PubMed:19224921). Interacts with
CC       PAPOLA (PubMed:19224921). Interacts with ZCCHC4 (PubMed:31799605).
CC       {ECO:0000250|UniProtKB:B5DFN2, ECO:0000250|UniProtKB:Q80SW1,
CC       ECO:0000269|PubMed:16769890, ECO:0000269|PubMed:16793548,
CC       ECO:0000269|PubMed:18829453, ECO:0000269|PubMed:19220705,
CC       ECO:0000269|PubMed:19224921, ECO:0000269|PubMed:20584908,
CC       ECO:0000269|PubMed:25237103, ECO:0000269|PubMed:27995898,
CC       ECO:0000269|PubMed:31799605}.
CC   -!- INTERACTION:
CC       O43865; O43865: AHCYL1; NbExp=5; IntAct=EBI-2371423, EBI-2371423;
CC       O43865; Q9HD36: BCL2L10; NbExp=4; IntAct=EBI-2371423, EBI-2126349;
CC       O43865; P55957: BID; NbExp=3; IntAct=EBI-2371423, EBI-519672;
CC       O43865; P55957-2: BID; NbExp=3; IntAct=EBI-2371423, EBI-10215147;
CC       O43865; P42773: CDKN2C; NbExp=10; IntAct=EBI-2371423, EBI-711290;
CC       O43865; Q9UI36-2: DACH1; NbExp=10; IntAct=EBI-2371423, EBI-10186082;
CC       O43865; P55040: GEM; NbExp=8; IntAct=EBI-2371423, EBI-744104;
CC       O43865; P09105: HBQ1; NbExp=6; IntAct=EBI-2371423, EBI-10193656;
CC       O43865; Q96MH2: HEXIM2; NbExp=4; IntAct=EBI-2371423, EBI-5460660;
CC       O43865; P17066: HSPA6; NbExp=3; IntAct=EBI-2371423, EBI-355106;
CC       O43865; Q14643: ITPR1; NbExp=3; IntAct=EBI-2371423, EBI-465548;
CC       O43865; Q8TAC2: JOSD2; NbExp=4; IntAct=EBI-2371423, EBI-12205593;
CC       O43865; Q5S007: LRRK2; NbExp=3; IntAct=EBI-2371423, EBI-5323863;
CC       O43865; P43356: MAGEA2B; NbExp=3; IntAct=EBI-2371423, EBI-5650739;
CC       O43865; P50222: MEOX2; NbExp=3; IntAct=EBI-2371423, EBI-748397;
CC       O43865; Q8NCR3: MFI; NbExp=3; IntAct=EBI-2371423, EBI-744790;
CC       O43865; Q8N323: NXPE1; NbExp=3; IntAct=EBI-2371423, EBI-25834085;
CC       O43865; Q8N2W9: PIAS4; NbExp=3; IntAct=EBI-2371423, EBI-473160;
CC       O43865; O94827-4: PLEKHG5; NbExp=3; IntAct=EBI-2371423, EBI-11980215;
CC       O43865; O14829: PPEF1; NbExp=3; IntAct=EBI-2371423, EBI-2931238;
CC       O43865; O60437: PPL; NbExp=3; IntAct=EBI-2371423, EBI-368321;
CC       O43865; Q9NQX0: PRDM6; NbExp=3; IntAct=EBI-2371423, EBI-11320284;
CC       O43865; O00233: PSMD9; NbExp=3; IntAct=EBI-2371423, EBI-750973;
CC       O43865; A0A0S2Z4G9: RNF6; NbExp=3; IntAct=EBI-2371423, EBI-16428950;
CC       O43865; Q9UHI7: SLC23A1; NbExp=3; IntAct=EBI-2371423, EBI-1759386;
CC       O43865; Q9UHI7-3: SLC23A1; NbExp=3; IntAct=EBI-2371423, EBI-11998660;
CC       O43865; Q02978: SLC25A11; NbExp=3; IntAct=EBI-2371423, EBI-359174;
CC       O43865; O94993: SOX30; NbExp=3; IntAct=EBI-2371423, EBI-742973;
CC       O43865; P48775: TDO2; NbExp=3; IntAct=EBI-2371423, EBI-743494;
CC       O43865; Q9BZF9: UACA; NbExp=3; IntAct=EBI-2371423, EBI-350510;
CC       O43865; P49910: ZNF165; NbExp=3; IntAct=EBI-2371423, EBI-741694;
CC       O43865; Q53Z40: ZNF165; NbExp=5; IntAct=EBI-2371423, EBI-10186058;
CC       O43865; P04608: tat; Xeno; NbExp=5; IntAct=EBI-2371423, EBI-6164389;
CC   -!- SUBCELLULAR LOCATION: Endoplasmic reticulum
CC       {ECO:0000269|PubMed:27995898}. Cytoplasm, cytosol
CC       {ECO:0000269|PubMed:27995898}. Apical cell membrane
CC       {ECO:0000250|UniProtKB:B5DFN2}; Peripheral membrane protein
CC       {ECO:0000305}. Microsome {ECO:0000250|UniProtKB:Q80SW1}.
CC       Note=Associates with membranes when phosphorylated, probably through
CC       interaction with ITPR1 (By similarity). Localizes to mitochondria-
CC       associated endoplasmic reticulum membranes (MAMs) (PubMed:27995898).
CC       Localization to MAMs is greatly reduced under apoptotic stress
CC       conditions (PubMed:27995898). {ECO:0000250|UniProtKB:Q80SW1,
CC       ECO:0000269|PubMed:27995898}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=O43865-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=O43865-2; Sequence=VSP_021751;
CC   -!- TISSUE SPECIFICITY: Expressed in dendritic cells.
CC       {ECO:0000269|PubMed:11904675}.
CC   -!- DEVELOPMENTAL STAGE: Expression increases markedly during activation of
CC       blood and skin DC (Langerhans cells), but is diminished in terminally
CC       differentiated tonsil DC. {ECO:0000269|PubMed:11904675}.
CC   -!- DOMAIN: The PEST region is essential for the interaction with ITPR1,
CC       and, when phosphorylated, is also the RRM1-binding region. The PDZ-
CC       binding region is required for maximal interaction with ITPR1 and is
CC       also responsible for the IP3-insensitive interaction with ITPR1 (By
CC       similarity). {ECO:0000250|UniProtKB:Q80SW1,
CC       ECO:0000269|PubMed:25237103}.
CC   -!- PTM: Phosphorylated at Ser/Thr residues between Ser-68 and Thr-72 in
CC       the PEST region: required for interaction with dATP-bound RRM1 and
CC       ITPR1. Phosphorylation at Ser-68 by PRKD1 and CAMK4 is required for
CC       further phosphorylations by CSNK1A1 (PubMed:16793548). Phosphorylation
CC       is induced by oxidative stress (PubMed:19224921). Probably
CC       phosphorylated by CAMK2A; phosphorylation at Ser-68 may be required for
CC       interaction with SLC9A3 (PubMed:20584908). Dephosphorylated in response
CC       to apoptotic stress conditions which causes translocation of both
CC       AHCYL1 and BCL2L10 from mitochondria-associated endoplasmic reticulum
CC       membranes and promotes apoptosis (PubMed:27995898).
CC       {ECO:0000269|PubMed:16793548, ECO:0000269|PubMed:19224921,
CC       ECO:0000269|PubMed:25237103, ECO:0000269|PubMed:27995898,
CC       ECO:0000305|PubMed:20584908}.
CC   -!- MISCELLANEOUS: Ablation of expression in HeLa cells causes imbalanced
CC       dNTP pools and altered cell cycle progression.
CC       {ECO:0000269|PubMed:25237103}.
CC   -!- SIMILARITY: Belongs to the adenosylhomocysteinase family.
CC       {ECO:0000305}.
CC   -!- CAUTION: In spite of its similarity with AHCY, which catalyzes the
CC       reversible hydrolysis of S-adenosyl-L-homocysteine to adenosine and
CC       homocysteine, recombinant AHCYL1 expressed in bacteria shows no
CC       hydrolase activity, nor does it affect the enzyme activity of AHCY.
CC       {ECO:0000250|UniProtKB:Q80SW1}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAC01960.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305};
CC       Sequence=BI460083; Type=Frameshift; Evidence={ECO:0000305};
CC       Sequence=CAB43223.2; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF315687; AAL26869.1; -; mRNA.
DR   EMBL; AL036027; -; NOT_ANNOTATED_CDS; mRNA.
DR   EMBL; AK303690; BAG64680.1; -; mRNA.
DR   EMBL; AK316110; BAH14481.1; -; mRNA.
DR   EMBL; AL049954; CAB43223.2; ALT_INIT; mRNA.
DR   EMBL; AL772411; CAH70965.1; -; Genomic_DNA.
DR   EMBL; AL772411; CAH70966.1; -; Genomic_DNA.
DR   EMBL; CH471122; EAW56426.1; -; Genomic_DNA.
DR   EMBL; BC007576; AAH07576.3; -; mRNA.
DR   EMBL; BC010681; AAH10681.3; -; mRNA.
DR   EMBL; BC016942; AAH16942.3; -; mRNA.
DR   EMBL; BC065254; AAH65254.2; -; mRNA.
DR   EMBL; BC095476; AAH95476.2; -; mRNA.
DR   EMBL; BC110896; AAI10897.2; -; mRNA.
DR   EMBL; BI460083; -; NOT_ANNOTATED_CDS; mRNA.
DR   EMBL; U82761; AAC01960.1; ALT_INIT; mRNA.
DR   EMBL; AU279527; -; NOT_ANNOTATED_CDS; mRNA.
DR   EMBL; T19009; -; NOT_ANNOTATED_CDS; mRNA.
DR   EMBL; BK005418; DAA05763.1; -; mRNA.
DR   EMBL; BK005417; DAA05762.1; -; mRNA.
DR   CCDS; CCDS55620.1; -. [O43865-2]
DR   CCDS; CCDS818.1; -. [O43865-1]
DR   PIR; T08681; T08681.
DR   RefSeq; NP_001229602.1; NM_001242673.1. [O43865-2]
DR   RefSeq; NP_001229603.1; NM_001242674.1. [O43865-2]
DR   RefSeq; NP_001229604.1; NM_001242675.1. [O43865-2]
DR   RefSeq; NP_001229605.1; NM_001242676.1. [O43865-2]
DR   RefSeq; NP_006612.2; NM_006621.5. [O43865-1]
DR   PDB; 3MTG; X-ray; 2.64 A; A/B=89-530.
DR   PDBsum; 3MTG; -.
DR   SMR; O43865; -.
DR   BioGRID; 115987; 239.
DR   IntAct; O43865; 78.
DR   MINT; O43865; -.
DR   STRING; 9606.ENSP00000358814; -.
DR   BindingDB; O43865; -.
DR   ChEMBL; CHEMBL3751646; -.
DR   iPTMnet; O43865; -.
DR   MetOSite; O43865; -.
DR   PhosphoSitePlus; O43865; -.
DR   BioMuta; AHCYL1; -.
DR   EPD; O43865; -.
DR   jPOST; O43865; -.
DR   MassIVE; O43865; -.
DR   MaxQB; O43865; -.
DR   PaxDb; O43865; -.
DR   PeptideAtlas; O43865; -.
DR   PRIDE; O43865; -.
DR   ProteomicsDB; 49211; -. [O43865-1]
DR   ProteomicsDB; 49212; -. [O43865-2]
DR   Antibodypedia; 33777; 179 antibodies.
DR   DNASU; 10768; -.
DR   Ensembl; ENST00000359172; ENSP00000352092; ENSG00000168710. [O43865-2]
DR   Ensembl; ENST00000369799; ENSP00000358814; ENSG00000168710. [O43865-1]
DR   Ensembl; ENST00000393614; ENSP00000377238; ENSG00000168710. [O43865-2]
DR   GeneID; 10768; -.
DR   KEGG; hsa:10768; -.
DR   UCSC; uc001dyx.4; human. [O43865-1]
DR   CTD; 10768; -.
DR   DisGeNET; 10768; -.
DR   GeneCards; AHCYL1; -.
DR   HGNC; HGNC:344; AHCYL1.
DR   HPA; ENSG00000168710; Low tissue specificity.
DR   MIM; 607826; gene.
DR   neXtProt; NX_O43865; -.
DR   OpenTargets; ENSG00000168710; -.
DR   PharmGKB; PA24637; -.
DR   VEuPathDB; HostDB:ENSG00000168710.17; -.
DR   eggNOG; KOG1370; Eukaryota.
DR   GeneTree; ENSGT00950000182981; -.
DR   HOGENOM; CLU_025194_2_1_1; -.
DR   InParanoid; O43865; -.
DR   OMA; MSEPVGE; -.
DR   PhylomeDB; O43865; -.
DR   TreeFam; TF300415; -.
DR   PathwayCommons; O43865; -.
DR   Reactome; R-HSA-112043; PLC beta mediated events.
DR   Reactome; R-HSA-1489509; DAG and IP3 signaling.
DR   Reactome; R-HSA-2029485; Role of phospholipids in phagocytosis.
DR   Reactome; R-HSA-2871809; FCERI mediated Ca+2 mobilization.
DR   Reactome; R-HSA-422356; Regulation of insulin secretion.
DR   Reactome; R-HSA-5218921; VEGFR2 mediated cell proliferation.
DR   Reactome; R-HSA-5578775; Ion homeostasis.
DR   Reactome; R-HSA-5607763; CLEC7A (Dectin-1) induces NFAT activation.
DR   Reactome; R-HSA-9664323; FCGR3A-mediated IL10 synthesis.
DR   Reactome; R-HSA-983695; Antigen activates B Cell Receptor (BCR) leading to generation of second messengers.
DR   SIGNOR; O43865; -.
DR   BioGRID-ORCS; 10768; 252 hits in 997 CRISPR screens.
DR   ChiTaRS; AHCYL1; human.
DR   EvolutionaryTrace; O43865; -.
DR   GeneWiki; AHCYL1; -.
DR   GenomeRNAi; 10768; -.
DR   Pharos; O43865; Tchem.
DR   PRO; PR:O43865; -.
DR   Proteomes; UP000005640; Chromosome 1.
DR   RNAct; O43865; protein.
DR   Bgee; ENSG00000168710; Expressed in hypothalamus and 253 other tissues.
DR   ExpressionAtlas; O43865; baseline and differential.
DR   Genevisible; O43865; HS.
DR   GO; GO:0016324; C:apical plasma membrane; ISS:UniProtKB.
DR   GO; GO:0005737; C:cytoplasm; ISS:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IBA:GO_Central.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; TAS:Reactome.
DR   GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB.
DR   GO; GO:0044233; C:mitochondria-associated endoplasmic reticulum membrane; IDA:UniProtKB.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0003723; F:RNA binding; IEA:UniProtKB-KW.
DR   GO; GO:0038166; P:angiotensin-activated signaling pathway; IDA:UniProtKB.
DR   GO; GO:0006915; P:apoptotic process; IMP:UniProtKB.
DR   GO; GO:0042045; P:epithelial fluid transport; IEA:Ensembl.
DR   GO; GO:1990456; P:mitochondrion-endoplasmic reticulum membrane tethering; IMP:UniProtKB.
DR   GO; GO:0006378; P:mRNA polyadenylation; IDA:UniProtKB.
DR   GO; GO:0006730; P:one-carbon metabolic process; IEA:UniProtKB-KW.
DR   GO; GO:0010765; P:positive regulation of sodium ion transport; IMP:UniProtKB.
DR   GO; GO:0006611; P:protein export from nucleus; IEA:Ensembl.
DR   GO; GO:0044070; P:regulation of anion transport; IEA:Ensembl.
DR   GO; GO:1903779; P:regulation of cardiac conduction; TAS:Reactome.
DR   GO; GO:0032412; P:regulation of ion transmembrane transporter activity; IMP:UniProtKB.
DR   GO; GO:0031440; P:regulation of mRNA 3'-end processing; IDA:UniProtKB.
DR   GO; GO:0051592; P:response to calcium ion; IDA:UniProtKB.
DR   GO; GO:0033353; P:S-adenosylmethionine cycle; IBA:GO_Central.
DR   CDD; cd00401; SAHH; 1.
DR   Gene3D; 3.40.50.1480; -; 2.
DR   InterPro; IPR042172; Adenosylhomocyst_ase-like_sf.
DR   InterPro; IPR000043; Adenosylhomocysteinase-like.
DR   InterPro; IPR015878; Ado_hCys_hydrolase_NAD-bd.
DR   InterPro; IPR036291; NAD(P)-bd_dom_sf.
DR   InterPro; IPR020082; S-Ado-L-homoCys_hydrolase_CS.
DR   PANTHER; PTHR23420; PTHR23420; 1.
DR   Pfam; PF05221; AdoHcyase; 1.
DR   Pfam; PF00670; AdoHcyase_NAD; 1.
DR   PIRSF; PIRSF001109; Ad_hcy_hydrolase; 1.
DR   SMART; SM00996; AdoHcyase; 1.
DR   SMART; SM00997; AdoHcyase_NAD; 1.
DR   SUPFAM; SSF51735; SSF51735; 1.
DR   TIGRFAMs; TIGR00936; ahcY; 1.
DR   PROSITE; PS00738; ADOHCYASE_1; 1.
DR   PROSITE; PS00739; ADOHCYASE_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; Cell membrane; Cytoplasm;
KW   Endoplasmic reticulum; Membrane; Microsome; NAD; One-carbon metabolism;
KW   Phosphoprotein; Reference proteome; RNA-binding.
FT   INIT_MET        1
FT                   /note="Removed"
FT                   /evidence="ECO:0007744|PubMed:21406692"
FT   CHAIN           2..530
FT                   /note="S-adenosylhomocysteine hydrolase-like protein 1"
FT                   /id="PRO_0000116908"
FT   NP_BIND         318..322
FT                   /note="NAD"
FT                   /evidence="ECO:0000269|PubMed:25237103"
FT   NP_BIND         397..399
FT                   /note="NAD"
FT                   /evidence="ECO:0000269|PubMed:25237103"
FT   REGION          65..92
FT                   /note="PEST"
FT                   /evidence="ECO:0000269|PubMed:25237103"
FT   REGION          138..201
FT                   /note="Interaction with BCL2L10"
FT                   /evidence="ECO:0000269|PubMed:27995898"
FT   REGION          281..448
FT                   /note="NAD binding"
FT                   /evidence="ECO:0000250"
FT   REGION          520..530
FT                   /note="PDZ-binding"
FT                   /evidence="ECO:0000250"
FT   BINDING         155
FT                   /note="Substrate"
FT                   /evidence="ECO:0000250"
FT   BINDING         229
FT                   /note="Substrate"
FT                   /evidence="ECO:0000250"
FT   BINDING         254
FT                   /note="Substrate"
FT                   /evidence="ECO:0000250"
FT   BINDING         284
FT                   /note="Substrate"
FT                   /evidence="ECO:0000250"
FT   BINDING         288
FT                   /note="Substrate"
FT                   /evidence="ECO:0000250"
FT   BINDING         341
FT                   /note="NAD"
FT                   /evidence="ECO:0000269|PubMed:25237103"
FT   BINDING         376
FT                   /note="NAD"
FT                   /evidence="ECO:0000269|PubMed:25237103"
FT   MOD_RES         2
FT                   /note="N-acetylserine"
FT                   /evidence="ECO:0007744|PubMed:21406692"
FT   MOD_RES         2
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:21406692,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         40
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:Q80SW1"
FT   MOD_RES         68
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:27995898,
FT                   ECO:0000305|PubMed:16793548, ECO:0000305|PubMed:19220705"
FT   MOD_RES         71
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:27995898,
FT                   ECO:0000305|PubMed:16793548, ECO:0000305|PubMed:19220705"
FT   MOD_RES         74
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:27995898,
FT                   ECO:0000305|PubMed:19220705"
FT   MOD_RES         77
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:27995898,
FT                   ECO:0000305|PubMed:19220705"
FT   MOD_RES         84
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q80SW1"
FT   MOD_RES         391
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648"
FT   VAR_SEQ         1..47
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:12878157,
FT                   ECO:0000303|PubMed:14702039, ECO:0000303|PubMed:15489334,
FT                   ECO:0000303|PubMed:17974005, ECO:0000303|PubMed:7782076"
FT                   /id="VSP_021751"
FT   MUTAGEN         52
FT                   /note="T->A: No effect on interaction with SLC4A4."
FT                   /evidence="ECO:0000269|PubMed:16769890"
FT   MUTAGEN         58
FT                   /note="T->A: No effect on interaction with SLC4A4."
FT                   /evidence="ECO:0000269|PubMed:16769890"
FT   MUTAGEN         62
FT                   /note="S->A: No effect on interaction with SLC4A4. No
FT                   effect on interaction with FIP1L1."
FT                   /evidence="ECO:0000269|PubMed:16769890,
FT                   ECO:0000269|PubMed:19224921"
FT   MUTAGEN         64
FT                   /note="S->A: No effect on interaction with ITPR1. No effect
FT                   on phosphorylation. No effect on interaction with SLC4A4.
FT                   No effect on interaction with FIP1L1."
FT                   /evidence="ECO:0000269|PubMed:16769890,
FT                   ECO:0000269|PubMed:16793548, ECO:0000269|PubMed:19224921"
FT   MUTAGEN         66
FT                   /note="S->A: Slightly decreases interaction with ITPR1.
FT                   Slightly decreases phosphorylation. No effect on
FT                   interaction with SLC4A4. Abolishes interaction with
FT                   FIP1L1."
FT                   /evidence="ECO:0000269|PubMed:16769890,
FT                   ECO:0000269|PubMed:16793548, ECO:0000269|PubMed:19224921"
FT   MUTAGEN         68
FT                   /note="S->A: Highly decreases phosphorylation. Abolishes
FT                   interaction with ITPR1. No effect on interaction with
FT                   BCL2L10. Marked decrease in interaction of BCL2L10 with
FT                   ITPR1. Decreased ability of BCL2L10 to reduce ITPR1-
FT                   mediated calcium release and to prevent apoptosis. No
FT                   effect on formation of multimers. Abolishes interaction
FT                   with SLC4A4. Abolishes interaction with FIP1L1. Highly
FT                   decreases interaction with SLC9A3. Highly decreases
FT                   interaction with SLC9A3; when associated with A-71 and A-
FT                   74."
FT                   /evidence="ECO:0000269|PubMed:16769890,
FT                   ECO:0000269|PubMed:16793548, ECO:0000269|PubMed:19224921,
FT                   ECO:0000269|PubMed:20584908, ECO:0000269|PubMed:27995898"
FT   MUTAGEN         70
FT                   /note="S->A: Highly decreases interaction with ITPR1. No
FT                   effect on phosphorylation. No effect on interaction with
FT                   SLC4A4. Abolishes interaction with FIP1L1."
FT                   /evidence="ECO:0000269|PubMed:16769890,
FT                   ECO:0000269|PubMed:16793548, ECO:0000269|PubMed:19224921"
FT   MUTAGEN         71
FT                   /note="S->A: Abolishes interaction with ITPR1. Highly
FT                   decreases phosphorylation. Abolishes interaction with
FT                   SLC4A4. Abolishes interaction with FIP1L1. Highly decreases
FT                   interaction with SLC9A3; when associated whith A-68 and A-
FT                   74."
FT                   /evidence="ECO:0000269|PubMed:16769890,
FT                   ECO:0000269|PubMed:16793548, ECO:0000269|PubMed:19224921,
FT                   ECO:0000269|PubMed:20584908"
FT   MUTAGEN         72
FT                   /note="T->A: Highly decreases interaction with ITPR1.
FT                   Slightly increases phosphorylation. No effect on
FT                   interaction with SLC4A4. Highly decreases interaction with
FT                   FIP1L1."
FT                   /evidence="ECO:0000269|PubMed:16769890,
FT                   ECO:0000269|PubMed:16793548, ECO:0000269|PubMed:19224921"
FT   MUTAGEN         74
FT                   /note="S->G: Abolishes interaction with ITPR1. Slightly
FT                   decreases phosphorylation. Strongly decreases interaction
FT                   with SLC4A4. Abolishes interaction with FIP1L1. Highly
FT                   decreases interaction with SLC9A3; when associated whith A-
FT                   68 and A-71."
FT                   /evidence="ECO:0000269|PubMed:16769890,
FT                   ECO:0000269|PubMed:16793548, ECO:0000269|PubMed:19224921,
FT                   ECO:0000269|PubMed:20584908"
FT   MUTAGEN         76
FT                   /note="S->G: No effect on interaction with ITPR1. No effect
FT                   on phosphorylation. No effect on interaction with SLC4A4.
FT                   No effect on interaction with FIP1L1."
FT                   /evidence="ECO:0000269|PubMed:16769890,
FT                   ECO:0000269|PubMed:16793548, ECO:0000269|PubMed:19224921"
FT   MUTAGEN         77
FT                   /note="S->A: Highly decreases interaction with ITPR1.
FT                   Slightly decreases phosphorylation. Strongly decreases
FT                   interaction with SLC4A4. Abolishes interaction with
FT                   FIP1L1."
FT                   /evidence="ECO:0000269|PubMed:16769890,
FT                   ECO:0000269|PubMed:16793548, ECO:0000269|PubMed:19224921"
FT   MUTAGEN         80
FT                   /note="S->A: No effect on interaction with SLC4A4. Highly
FT                   decreases interaction with FIP1L1."
FT                   /evidence="ECO:0000269|PubMed:16769890,
FT                   ECO:0000269|PubMed:16793548, ECO:0000269|PubMed:19224921"
FT   MUTAGEN         82
FT                   /note="T->A: No effect on interaction with ITPR1. No effect
FT                   on phosphorylation. No effect on interaction with SLC4A4.
FT                   Decreases interaction with FIP1L1."
FT                   /evidence="ECO:0000269|PubMed:16769890,
FT                   ECO:0000269|PubMed:16793548, ECO:0000269|PubMed:19224921"
FT   MUTAGEN         84
FT                   /note="S->A: Slightly decreases interaction with ITPR1. No
FT                   effect on phosphorylation. No effect on interaction with
FT                   SLC4A4. Decreases interaction with FIP1L1."
FT                   /evidence="ECO:0000269|PubMed:16769890,
FT                   ECO:0000269|PubMed:16793548, ECO:0000269|PubMed:19224921"
FT   MUTAGEN         85
FT                   /note="S->A: Slightly decreases interaction with ITPR1. No
FT                   effect on phosphorylation. No effect on interaction with
FT                   SLC4A4. Decreases interaction with FIP1L1."
FT                   /evidence="ECO:0000269|PubMed:16769890,
FT                   ECO:0000269|PubMed:16793548, ECO:0000269|PubMed:19224921"
FT   MUTAGEN         90
FT                   /note="S->A: No effect on interaction with ITPR1. No effect
FT                   on phosphorylation. No effect on interaction with SLC4A4.
FT                   No effect on interaction with FIP1L1."
FT                   /evidence="ECO:0000269|PubMed:16769890,
FT                   ECO:0000269|PubMed:16793548, ECO:0000269|PubMed:19224921"
FT   MUTAGEN         97
FT                   /note="T->A: No effect on interaction with ITPR1. No effect
FT                   on interaction with SLC4A4. No effect on interaction with
FT                   FIP1L1."
FT                   /evidence="ECO:0000269|PubMed:16769890,
FT                   ECO:0000269|PubMed:16793548, ECO:0000269|PubMed:19224921"
FT   CONFLICT        94
FT                   /note="K -> M (in Ref. 9; T19009)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        99
FT                   /note="S -> F (in Ref. 9; T19009)"
FT                   /evidence="ECO:0000305"
FT   HELIX           113..124
FT                   /evidence="ECO:0007744|PDB:3MTG"
FT   HELIX           128..137
FT                   /evidence="ECO:0007744|PDB:3MTG"
FT   TURN            142..145
FT                   /evidence="ECO:0007744|PDB:3MTG"
FT   STRAND          147..152
FT                   /evidence="ECO:0007744|PDB:3MTG"
FT   HELIX           156..167
FT                   /evidence="ECO:0007744|PDB:3MTG"
FT   STRAND          171..175
FT                   /evidence="ECO:0007744|PDB:3MTG"
FT   STRAND          177..180
FT                   /evidence="ECO:0007744|PDB:3MTG"
FT   HELIX           184..193
FT                   /evidence="ECO:0007744|PDB:3MTG"
FT   STRAND          196..198
FT                   /evidence="ECO:0007744|PDB:3MTG"
FT   HELIX           205..216
FT                   /evidence="ECO:0007744|PDB:3MTG"
FT   STRAND          224..231
FT                   /evidence="ECO:0007744|PDB:3MTG"
FT   HELIX           232..240
FT                   /evidence="ECO:0007744|PDB:3MTG"
FT   HELIX           242..245
FT                   /evidence="ECO:0007744|PDB:3MTG"
FT   STRAND          249..253
FT                   /evidence="ECO:0007744|PDB:3MTG"
FT   HELIX           256..265
FT                   /evidence="ECO:0007744|PDB:3MTG"
FT   TURN            266..269
FT                   /evidence="ECO:0007744|PDB:3MTG"
FT   STRAND          275..277
FT                   /evidence="ECO:0007744|PDB:3MTG"
FT   HELIX           282..293
FT                   /evidence="ECO:0007744|PDB:3MTG"
FT   HELIX           299..305
FT                   /evidence="ECO:0007744|PDB:3MTG"
FT   STRAND          313..317
FT                   /evidence="ECO:0007744|PDB:3MTG"
FT   HELIX           321..333
FT                   /evidence="ECO:0007744|PDB:3MTG"
FT   STRAND          336..340
FT                   /evidence="ECO:0007744|PDB:3MTG"
FT   HELIX           344..352
FT                   /evidence="ECO:0007744|PDB:3MTG"
FT   HELIX           360..362
FT                   /evidence="ECO:0007744|PDB:3MTG"
FT   TURN            363..366
FT                   /evidence="ECO:0007744|PDB:3MTG"
FT   STRAND          368..372
FT                   /evidence="ECO:0007744|PDB:3MTG"
FT   HELIX           382..387
FT                   /evidence="ECO:0007744|PDB:3MTG"
FT   STRAND          392..396
FT                   /evidence="ECO:0007744|PDB:3MTG"
FT   TURN            400..403
FT                   /evidence="ECO:0007744|PDB:3MTG"
FT   HELIX           406..409
FT                   /evidence="ECO:0007744|PDB:3MTG"
FT   STRAND          415..420
FT                   /evidence="ECO:0007744|PDB:3MTG"
FT   STRAND          423..427
FT                   /evidence="ECO:0007744|PDB:3MTG"
FT   STRAND          433..437
FT                   /evidence="ECO:0007744|PDB:3MTG"
FT   HELIX           438..440
FT                   /evidence="ECO:0007744|PDB:3MTG"
FT   HELIX           444..446
FT                   /evidence="ECO:0007744|PDB:3MTG"
FT   HELIX           452..471
FT                   /evidence="ECO:0007744|PDB:3MTG"
FT   STRAND          479..482
FT                   /evidence="ECO:0007744|PDB:3MTG"
FT   HELIX           486..496
FT                   /evidence="ECO:0007744|PDB:3MTG"
FT   HELIX           497..500
FT                   /evidence="ECO:0007744|PDB:3MTG"
FT   HELIX           509..514
FT                   /evidence="ECO:0007744|PDB:3MTG"
FT   STRAND          519..521
FT                   /evidence="ECO:0007744|PDB:3MTG"
FT   MOD_RES         O43865-2:1
FT                   /note="N-acetylmethionine"
FT                   /evidence="ECO:0007744|PubMed:22814378"
SQ   SEQUENCE   530 AA;  58951 MW;  974D23361A245D04 CRC64;
     MSMPDAMPLP GVGEELKQAK EIEDAEKYSF MATVTKAPKK QIQFADDMQE FTKFPTKTGR
     RSLSRSISQS STDSYSSAAS YTDSSDDEVS PREKQQTNSK GSSNFCVKNI KQAEFGRREI
     EIAEQDMSAL ISLRKRAQGE KPLAGAKIVG CTHITAQTAV LIETLCALGA QCRWSACNIY
     STQNEVAAAL AEAGVAVFAW KGESEDDFWW CIDRCVNMDG WQANMILDDG GDLTHWVYKK
     YPNVFKKIRG IVEESVTGVH RLYQLSKAGK LCVPAMNVND SVTKQKFDNL YCCRESILDG
     LKRTTDVMFG GKQVVVCGYG EVGKGCCAAL KALGAIVYIT EIDPICALQA CMDGFRVVKL
     NEVIRQVDVV ITCTGNKNVV TREHLDRMKN SCIVCNMGHS NTEIDVTSLR TPELTWERVR
     SQVDHVIWPD GKRVVLLAEG RLLNLSCSTV PTFVLSITAT TQALALIELY NAPEGRYKQD
     VYLLPKKMDE YVASLHLPSF DAHLTELTDD QAKYLGLNKN GPFKPNYYRY
//
